An improved synthesis of the ketonucleoside 2‘-Oxo-3‘,5‘- O -[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-cytidine ( 6 ), an intermediate in the synthesis of the potent anti-tumor agent 1 (MDL 101,731 or FMdC), is reported which incorporates a trifluoroacetic acid/dimethylsulfoxide oxidation process. This oxidation procedure eliminates the cryogenic reaction conditions and the necessity of protection at the N-4 amine used in the previously published route. Simplified isolation procedures for 3 and 4 eliminate two chromatographic purification steps. Overall yields are comparable to those reported previously.
No takes yet. Share an insight, caveat, or question.
Appell et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: